|
Real0ne -> RE: The Great Cancer Hoax: (6/11/2011 10:43:10 PM)
|
quote:
ORIGINAL: DomKen
quote:
ORIGINAL: subfever
quote:
ORIGINAL: DomKen
Burzynski is a fraud artist. He fakes his data. Otherwise other doctors could replicate his treatments and get similiar results (they have never been able to).
but but but kenny they did get the same results!
It would behoove you to at least watch the documentary first, as it clearly dispels your false notions with very convincing evidence.
I've read the actual papers. I've also followed the fact that serious cancer researchers tried to follow his protocol and had nothing like his claimed success rates. One basic inescapable fact is that science is not valid if it cannot be reproduced.
but but but kenny they did get the same results!
Have you considered hiring someone to read and explain it to you for substance?
if he were such a fraud why did they try to undermine his patents?
Oncol Rep. 2005 Aug;14(2):489-94.
Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells.
Fujii T, Nakamura AM, Yokoyama G, Yamaguchi M, Tayama K, Miwa K, Toh U, Kawamura D, Shirouzu K, Yamana H, Kuwano M, Tsuda H.
Our findings indicate that the antineoplaston A10 antitumor effect could be utilized as an effective therapy for breast cancer patients.
Seems to work here? Maybe they were not serious enough think?
--------------
Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case.
Ogata Y, Tsuda H, Matono K, Kumabe T, Saitsu H, Hara H, Akagi Y, Araki Y, Sata M, Shirouzu K.
Source
Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan.
has survived for nearly 8 years without suffering any serious adverse effects. He is currently free from cancer. This case report demonstrates the potential effectiveness of the nontoxic antitumor agent, the antineoplastons, for controlling liver metastases from colon cancer.
Seems to work here? Maybe they were not serious enough think?
------------------
A novel strategy for remission induction and maintenance in cancer therapy.
Tsuda H, Sata M, Ijuuin H, Kumabe T, Uchida M, Ogou Y, Akagi Y, Shirouzu K, Hara H, Nakashima Y.
Source
Department of Anesthesiology, Kurume University, School of Medicine, Fukuoka-ken 830-0011, Japan. [email protected]
This strategy would be most efficient for remission induction and maintenance in cancer therapy. Antineoplastons are naturally occurring peptides and amino acid derivatives that control neoplastic growth. Antineoplaston A10 and AS2-1 are chemically identified and synthesized antineoplastons proven to inhibit cancer cell growth by arresting the cell cycle in the G1 phase and inhibiting tumor growth by reducing mitosis. These agents are thought to be good candidates for clinically easily applicable non-toxic p53 gene activators.
Seems to work here? Maybe they were not serious enough think?
-----------------
Potential utility of antineoplaston A-10 levels in breast cancer.
Badria F, Mabed M, Khafagy W, Abou-Zeid L.
Source
Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Significantly lower antineoplaston A-10 levels were detected among patients with breast cancer with a P value <0.001. These data suggest a strong inverse association of urinary antineoplaston A-10 level with breast cancer.
Gee Ken just like Bursynski said huh!
Seems to work here? Now we know those Egyptians were not serious at all!!
------------------
Quick response of advanced cancer to chemoradiation therapy with antineoplastons.
Tsuda H, Sata M, Kumabe T, Hara H, Eriguchi N, Sugita Y, Nagamatsu H.
Source
Department of Anesthesiology, Kurume University, School of Medicine, 67 Asahimachi, Kurumeshi, Fukuokaken, 830, Japan.
Abstract
Antineoplastons A10 and AS2-1 exhibit growth inhibition of cancer cells by diverse modes of action. We observed antitumor responses within 2-3 weeks of a combination treatment of chemoradiation therapy and antineoplastons A10 and AS2-1 in phase I clinical study being conducted in Kurume University Hospital. We reviewed 3 clinical cases of advanced cancer (multiple metastatic lung cancer, thalamic glioma and primary lung cancer) in which we believed antineoplaston A10 and AS2-1 may be contributing to the rapid antitumor response. The possible use of this combination for induction therapy in advanced cancer is discussed.
Seems to work here? Maybe they were not serious enough think?
------------------
inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.
Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H.
Source
Department of Anesthesiology, Kurume University School of Medicine, Japan.
Abstract
Antineoplastons, first described by Burzynski, are naturally occurring peptides and amino acid derivatives which control neoplastic growth. Antineoplaston A10 (3-pehnylacetylamino-2,6-piperidinedion) is the first chemically identified antineoplastons and when it is administered orally it is hydrolysed in pancreatic juice to phenylactylglutamine and phenylacetylisoglutamine in the ration of 4 to 1. These metabolites are water soluble and have antitumor effect, they are further degraded to pehnylacetic acid. The mixture of phenylacetylglutamine and phenylacetylisoglutamine in the ratio of 4 to 1 was formulated as Antineoplaston A10 injectable formulation. The mixture of phenylacetylglutamine and phenylacetic acid in the ratio of 1 to 4 was also shown to have antitumor effect in tissue culture study, then formulated as Antineoplaston AS2-1. The reported cytostatic inhibitory effect of A10 on human hepatocellular carcinoma cells and differentiation inducing effect of AS2-1 on various tumor cells suggest potential benefit for the treatment of human hepatocellular carcinoma since this tumor recurs frequently despite initial successful treatment. We report here the effects of Antineoplaston A10 and AS2-1 on cell proliferation, cell morphology, cell cycle, and DNA in human hepatocellular carcinoma cell lines. Both agents inhibited cell proliferation and increased the number of cells in G0 and G1 phases and Antineoplaston AS2-1 induced apoptosis, we also describe our clinical experience of a hepatocellula carcinoma (HCC) patient whose tumor, after incomplete trancathere arterial embolization (TAE) for a 7cm 7cm HCC, has been stable for more than 15 months during which time he has been taking Antineoplaston AS2-1 continuously without any serious adverse effects.
Oh BTW; You are welcome!
|
|
|
|
